Stay updated with breaking news from Connection Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned safety analysis of the study data of 1,403 babies. We have now also received results from the pre-planned futility analysis. It is therefore with great...
Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study significantly increased in the final three months of...
Highlights Competitive EPC tenders received from a suite of highly experienced engineering firms. Boab to proceed to a competitive tendering ...
Message from the CEO IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants, gastrointestinal diseases and probiotics. We
Press release February 4, 2022 Message from the CEO IBT's ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities of premature infants. This is accomplished